Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical Advisory Committees Advertising, Marketing & Sales

Simeprevir Clears FDA, But Tougher Road Lies Ahead

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Unlike HCV competitors Incivek and Victrelis, Janssen’s second-generation protease inhibitor Olysio carries a recommendation for screening to weed out patients with a hepatitis C variant associated with poor response – but the strength of its efficacy and safety should still beat out those drugs. The harder part will be gaining share as patients are opting to wait for even better regimens.

Table

View full table

Advertisement

Related Content

Pink Sheet
Incivek Black Box Creates Fallout Risk For Vertex, FDA On Rash-related Fatalities

Topics

Related Companies

Advertisement
Tags:
BioPharmaceutical Advisory Committees Advertising, Marketing & Sales
UsernamePublicRestriction

Register

PS075087

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By